Developing Gene Therapies for Rare Diseases
The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s lead programs and future plans.
Real-World Efficacy of Brexucabtagene Autoleucel in Mantle Cell Lymphoma: Luhua Wang, MD
The professor from University of Texas MD Anderson Cancer Center discussed the real-world efficacy of the first CAR T therapy for the treatment of mantle cell lymphoma.
CAR T Therapy as a New Option in Non-Hodgkin Lymphoma: Michael R. Bishop, MD
The hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.
Future Research With NK and CAR T Therapy in Multiple Myeloma: Irene Ghobrial, MD
The director at Dana-Farber Cancer Institute discussed future efforts to prevent the development of multiple myeloma.
Improving Outcomes in AADC Deficiency With Gene Therapy: Paul Wuh-Liang Hwu, MD, PhD
The professor from National Taiwan University Hospital discussed further research he would like to do with the gene therapy PTC-AADC.
Personalized Vaccine-Based Therapy for Multiple Myeloma: Nina Shah, MD
The hematologist/oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential of vaccine-based therapies in multiple myeloma.
Efficient Gene Editing in Monogenic Diseases
André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s expansion into gene therapies.
Developing Safer, Next-Generation CAR T-Cell Therapies
Rick Fair, president and chief executive officer, Bellicum Pharmaceuticals, discussed the company’s programs and future plans.
Targeting CD19 With CAR T in R/R DL B-Cell Lymphoma: Brian T. Hill, MD, PhD; Mazyar Shadman, MD, MPH
Doctors from University of Washington and Cleveland Clinic discussed targeting CD19 in CAR T-cell therapy for relapsed/refractory DLBCL.
The Potential of Gene Therapy for AADC Deficiency: Paul Wuh-Liang Hwu, MD, PhD
The professor from National Taiwan University Hospital discussed the mechanism of gene therapy in AADC deficiency.
Developing Personalized Immunotherapies for Solid Tumors
Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the company’s focus on solid tumors and manufacturing cell therapies.
Improving Practicality of Cell and Gene Therapies
Josh Ludwig, global director, commercial operations, ScaleReady, discussed making cell and gene therapy widely practical and viable for patients with cancer.
Collaborating to Develop Oncologic Cell Therapies
André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s partnerships and science.
The Potential of ALLO-715 in Relapsed/Refractory Multiple Myeloma: Doris Hansen, MD
The hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.
Next Steps With CAR T-Cell Therapy in Multiple Myeloma: Omar Castaneda Puglianini, MD
The hematologist and medical oncologist discussed next steps with CAR T-cell therapy in penta-refractory multiple myeloma.
Potential of mRNA-Based Gene Therapies
Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s future research and plans.
Developing Customizable CAR T-Cell Therapies
Rick Fair, president and chief executive officer, Bellicum Pharmaceuticals, discussed the company’s GoCAR, iMC, and caspaCIDe technologies.
Gene Therapy Yields Improvements in AADC-Deficiency: Paul Wuh-Liang Hwu, MD, PhD
The professor from National Taiwan University Hospital discussed 3 studies of PTC-AADC for AADC deficiency.
CAR T-Cell Therapy and COVID-19 Vaccinations: Muhammad Bilal Abid, MD, MRCP
The assistant professor of medicine from Medical College of Wisconsin discussed the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.
The Future of Frontline CAR T in Mantle Cell Lymphoma: Brad S. Kahl, MD
The professor of medicine at Washington University School of Medicine in St. Louis discussed the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.
Access to Gene Therapies for Rare Diseases: Barry Byrne, MD, PhD
The director of the Powell Gene Therapy Center at the University of Florida discussed improving access to gene therapies for patients with rare diseases worldwide.
CAR T-Cell Therapy for Non-Hodgkin Lymphoma
The chief of oncology and hematology at University of Nebraska Medical Center discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.
Cilta-Cel Outcomes in R/R Multiple Myeloma: Omar Castaneda Puglianini, MD
The hematology and medical oncologist at Moffitt Cancer Center discussed results from the phase 1b/2 CARTITUDE-1 trial of cita-cel in R/R MM.
Multiple Myeloma KarMMA Trial Methodology: Larry Anderson, MD
The associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.
Ide-Cel's Benefit on PF Survival: Doris Hansen, MD
The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.
Identifying Patient-Specific Tumor Targets
Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.
CAR T Therapies for Hematologic Malignancies and Solid Tumors
André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed therapies the company is developing.
Brexucabtagene Autoleucel's Impact on MCL Treatment Landscape: Luhua Wang, MD
The professor from The University of Texas MD Anderson Cancer discussed the impact that brexucabtagene autoleucel's approval has had on mantle cell lymphoma.
Current Limitations of CAR T-Cell Therapy in Multiple Myeloma: Muhamed Baljevic, MD
The assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.
Advantages of mRNA-Based Gene Therapies
Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s technology and focus on mRNA therapies.
